Omega Diagnostics Group PLC Confirmation of detection of Omicron variant
14 Diciembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
14 December 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of detection of Omicron variant
VISITECT(R) COVID-19 antigen test performs with the same high
accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Global Health (CD4 and COVID-19) and
Health and Nutrition products, has been notified by its technology
partner Mologic Ltd ("Mologic") that data from analysis on clinical
samples, as well as in-silico analysis, show that the Mologic
Covios(R) Ag lateral flow test, performs with the same high
accuracy on the Omicron variant as it does with existing known
variants.
This is the same test that is manufactured and sold for
professional use by Omega as the VISITECT(R) COVID-19 antigen
test.
Colin King, CEO, Omega Diagnostics, said: "We are very pleased
be in a position to confirm that the VISITECT(R) COVID-19 antigen
test is able to equally detect the Omicron variant, as well as
other existing variants. We remain encouraged by emerging
commercial opportunities for our VISITECT(R) COVID-19 Antigen test
that we expect to be unlocked following relevant approval under
CTDA regulations and CE-marking for home-use."
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Colin King, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 75 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFFTFFLVLIL
(END) Dow Jones Newswires
December 14, 2021 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024